Parabilis Sets Biotech IPO Record
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
False
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
August 10, 2026
3 min read
Johnson & Johnson partners with Sail Biomedicines, an FDA advisory committee votes against deramiocel for Duchenne cardiomyopathy, and researchers uncover factors influencing CAR T and CAR NK outcomes
August 7, 2026
7 min read
Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier
August 6, 2026
7 min read
Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.
August 5, 2026
14 min read
In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development
False
Affiliations:
Specialties:
Areas of Expertise: